Read + Share
D'Haens G, Panaccione R, Baert F, Bossuyt P, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3
ADVANCE and MOTIVATE induction trials. Lancet 2022;399:2015-2030.
PMID: 35644154
|
 |
|
D'Haens G, Panaccione R, Baert F, Bossuyt P, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3
ADVANCE and MOTIVATE induction trials. Lancet 2022;399:2015-2030.
PMID: 35644154
|
|
|
|